Rheumatoid Arthritis
Conditions
Brief summary
The purpose is to study the relationship between RA disease activity based on Doppler quantification and the subsequent clinical response (EULAR response) to treatment with Adalimumab during 12 months. The purpose is also to compare the Doppler quantification with conventional clinical methods and semiquantitative Doppler assessment.
Interventions
BIOLOGICALAdalimumab
Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD
Sponsors
Abbott
Hamed Rezaei
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patient (\> 18 years of age), male or female * Rheumatoid arthritis according to the 1987 ACR or 2010 EULAR/ACR classification criteria * Moderate to high disease activity * Ongoing anti-rheumatic treatment with DMARD, with stable dosage during the last 3 months, and being a candidate for anti-TNF add-on therapy OR ongoing treatment with first anti-TNF therapy and being a candidate for switch to another anti-TNF therapy * Women with child-bearing potential: use of an adequate method of contraception to avoid pregnancy throughout the study * Signed Informed Consent \*Signed Informed Consent must be obtained before any study specific procedures take place.
Exclusion criteria
* Biologic treatment with Adalimumab before inclusion * Two or more ongoing biologic treatments before inclusion * Treatment with other biologic treatment than anti-TNF therapy before inclusion * Any contraindication for treatment with Adalimumab * Intraarticular corticosteroid injection during the last 4 weeks before each follow-up visit * Positive for tuberculosis or hepatitis B. * Ongoing pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of different clinical (EULAR) response | 6 months from BL | The primary endpoint will be the proportion of different clinical (EULAR) response (good, moderate, no response)\* to add-on therapy with anti-TNF treatment at 6 months follow-up visit in patients with activity versus in those without activity measured by Doppler ultrasound at baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of patients with good response to add-on therapy | 6 and 12 months from BL | The proportion of patients with good response to add-on therapy (measured by both Doppler and clinical assessment) at 6 and 12 months follow-up visits in two groups of patients, those who achieve low disease activity according to Doppler assessment at 3 months visit versus those who did not. |
Countries
Sweden
Outcome results
None listed